Edition:
United Kingdom

Biotechnology & Medical Research

Page 1

Celgene Is In Talks To Buy Juno Therapeutics -WSJ Reporter Tweet‍​

Tuesday, 16 Jan 2018

Jan 16 (Reuters) - :CELGENE IS IN TALKS TO BUY JUNO THERAPEUTICS -WSJ REPORTER TWEET‍​.

Human Stem Cells Institute Says Gets Control Over Icegen 2

Tuesday, 16 Jan 2018

Jan 16 (Reuters) - HUMAN STEM CELLS INSTITUTE ::SAYS GETS CONTROL OVER ICEGEN 2, RECEIVING 80.912 PCT STAKE IN THIS COMPANY.

Ablynx's Board Says Takeover Proposal From Novo Nordisk Undervalues Company

Monday, 8 Jan 2018

Jan 8 (Reuters) - ABLYNX NV ::BOARD UNANIMOUSLY CONCLUDED THAT PROPOSAL FUNDAMENTALLY UNDERVALUES ABLYNX AND ITS STRONG PROSPECTS FOR CONTINUED GROWTH AND VALUE CREATION.TODAY CONFIRMED THAT ON DEC 22, 2017 IT RECEIVED UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK A/S.J.P. MORGAN IS SERVING AS FINANCIAL ADVISOR TO ABLYNX.ABLYNX STRONGLY BELIEVES UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK FUNDAMENTALLY UNDERVALUES THE COMPANY AND ITS FUTURE PROSPECTS.CO LONG-TERM STRATEGIC PLAN OF BECOMING FULLY INTEGRATED BIOPHARMACEUTICAL COMPANY."BOARD SEES NO MERIT IN CEDING CONTROL OF ITS ASSETS WITHOUT FULL UPFRONT VALUE RECOGNITION FOR SHAREHOLDERS" - CEO.

Novo Nordisk CFO Says Not Our Understanding That Any Other Bidder Is Pursuing Ablynx

Monday, 8 Jan 2018

Jan 8 (Reuters) - NOVO NORDISK NOVOB.CO CHIEF FINANCIAL OFFICER JESPER BRANDGAARD SAID ON A CONFERENCE CALL IN RELATION TO BID FOR ABLYNX ::"IN TERMS OF COUNTER PROPOSALS IT IS NOT OUR UNDERSTANDING THAT ANY OTHER BIDDER IS PURSUING THE TARGET" nFWN1P3016.

Evotec, Apeiron Biologics receive milestone payment from Sanofi

Monday, 8 Jan 2018

Jan 8 (Reuters) - Evotec Ag ::SAYS ‍EVOTEC AND APEIRON ACHIEVE FIRST MILESTONE IN IMMUNO-ONCOLOGY ALLIANCE WITH SANOFI​.SAYS ‍MILESTONE PAYMENT OF EUR 3 M WILL BE SPLIT EQUALLY BETWEEN TWO BIOTECH COMPANIES​.SAYS ‍SUCCESS PAYMENT WAS TRIGGERED WHEN PARTNERS SUCCESSFULLY ADVANCED AN UNDISCLOSED, NOVEL IMMUNO-ONCOLOGY SMALL MOLECULE INTO LATE-STAGE PRE-CLINICAL DEVELOPMENT​.SAYS ‍UNDER ALLIANCE, THREE COMPANIES WORK TOGETHER TO IDENTIFY SMALL MOLECULE LEADS AND TARGETS FOR NEXT-GENERATION THERAPIES IN IMMUNO-ONCOLOGY​.

Acorda Therapeutics Is Exploring A Potential Sale - WSJ, Citing Sources

Friday, 5 Jan 2018

Jan 5 (Reuters) - Acorda Therapeutics Inc ::ACORDA THERAPEUTICS IS EXPLORING A POTENTIAL SALE - WSJ, CITING SOURCES.

Aslan Pharmaceuticals buys full global commercial rights for Varlitinib

Wednesday, 3 Jan 2018

Jan 3 (Reuters) - Aslan Pharmaceuticals Ltd <6497.TWO>::ASLAN PHARMACEUTICALS ACQUIRES FULL GLOBAL COMMERCIAL RIGHTS FOR VARLITINIB FROM ARRAY BIOPHARMA.ARRAY BIOPHARMA INC HAS GRANTED ASLAN FULL GLOBAL RIGHTS TO DEVELOP, MANUFACTURE AND COMMERCIALISE VARLITINIB​.ASLAN WILL MAKE AN UPFRONT PAYMENT OF $12 MILLION TO ARRAY ON SIGNATURE AND FURTHER PAYMENT OF UP TO $12 MILLION WITHIN NEXT 12 MONTHS​.ASLAN WILL MAKE UPFRONT PAYMENT TOGETHER WITH UP TO US$30 MILLION OF DEVELOPMENT AND US$75 MILLION OF COMMERCIAL MILESTONES.

Bio-Techne Acquires Atlanta Biologicals Inc

Tuesday, 2 Jan 2018

Jan 2 (Reuters) - Bio-Techne Corp ::BIO-TECHNE ACQUIRES ATLANTA BIOLOGICALS INC.BIO-TECHNE CORP - ‍TRANSACTION IS FINANCED THROUGH AVAILABLE CASH ON HAND​.BIO-TECHNE - DEAL EXPECTED TO BE SLIGHTLY ACCRETIVE TO ADJUSTED EARNINGS PER SHARE FOR FISCAL YEAR 2018.

Ani Pharmaceuticals Acquires Four NDAs From AstraZeneca For $46.5 Mln

Friday, 29 Dec 2017

Dec 29 (Reuters) - Ani Pharmaceuticals Inc ::ANI PHARMACEUTICALS ACQUIRES FOUR NDAS FROM ASTRAZENECA FOR $46.5 MILLION.ANI PHARMACEUTICALS INC - ACQUISITIONS WERE FUNDED THROUGH A COMBINATION OF CASH AND DEBT.ANI PHARMACEUTICALS SAYS ADDITION OF ASSETS WILL BE MATERIAL TO REVENUE AND EBITDA IN 2018.

Genscript Biotech Announces Acquisition Of Customarray

Tuesday, 26 Dec 2017

Dec 27 (Reuters) - Genscript Biotech Corp <1548.HK>::ANNOUNCES ACQUISITION OF 100% OF ENTIRE ISSUED SHARES OF CUSTOMARRAY, INC..

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary